Benznidazole prevents endothelial damage in an experimental model of Chagas disease

Acta Tropica

Volumn 127, Issue 1, 2013, Pages 6-13

  Molina Berríos, Alfredo ^a,b   Campos Estrada, Carolina ^b   Lapier, Michel ^b   Duaso, Juan ^b   Kemmerling, Ulrike ^b   Galanti, Norbel ^b   Leiva, Mario ^b   Ferreira, Jorge ^b   López Muñoz, Rodrigo ^b   Maya, Juan Diego ^b  

^a UNIVERSIDAD DIEGO PORTALES   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Chronic Chagas cardiomyopathy; Endothelial adhesion molecules; Soluble E selectin; Thromboxane A2; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; DNA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; THROMBOXANE A2;

CARDIOVASCULAR DISEASE; CHAGAS DISEASE; DISEASE CONTROL; DISEASE TREATMENT; DNA; DRUG PRESCRIBING; HISTOPATHOLOGY; MORTALITY; PARASITE; PROTEIN; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ENDOTHELIUM INJURY; HEART; HISTOPATHOLOGY; LOW DRUG DOSE; MALE; MORTALITY; MOUSE; NONHUMAN; PARASITEMIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; MALE; MICE; MICE, INBRED BALB C; NITROIMIDAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

MURINAE; MUS; TRYPANOSOMA CRUZI;

EID: 84875926509     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2013.03.006     Document Type: Article

References (45)

1. Al-Mutairi M., Al-Harthi S., Cadalbert L., Plevin R. Over-expression of mitogen-activated protein kinase phosphatase-2 enhances adhesion molecule expression and protects against apoptosis in human endothelial cells. Br. J. Pharmacol. 2010, 161:782-798.
2. Ashton A.W., Mukherjee S., Nagajyothi F.N., Huang H., Braunstein V.L., Desruisseaux M.S., Factor S.M., Lopez L., Berman J.W., Wittner M., Scherer P.E., Capra V., Coffman T.M., Serhan C.N., Gotlinger K., Wu K.K., Weiss L.M., Tanowitz H.B. Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection. J. Exp. Med. 2007, 204:929-940.
3. Barbosa A.P., Cardinalli Neto A., Otaviano A.P., Rocha B.F., Bestetti R.B. Comparison of outcome between Chagas cardiomyopathy and idiopathic dilated cardiomyopathy. Arq. Bras. Cardiol. 2011, 97:517-525.
4. Bryan M.A., Guyach S.E., Norris K.A. Specific humoral immunity versus polyclonal B cell activation in Trypanosoma cruzi infection of susceptible and resistant mice. PLoS Negl. Trop. Dis. 2010, 4:e733.
5. Bustamante J.M., Presti M.S., Rivarola H.W., Fernandez A.R., Enders J.E., Fretes R.E., Paglini-Oliva P. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy. Int. J. Antimicrob. Agents 2007, 29:733-737.
6. Caldas I.S., Talvani A., Caldas S., Carneiro C.M., de Lana M., da Matta Guedes P.M., Bahia M.T. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol. Res. 2008, 103:413-421.
7. Constans J., Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin. Chim. Acta 2006, 368:33-47.
8. Coura J.R., Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem. Inst. Oswaldo Cruz 2011, 106:641-645.
9. Daniel T.O., Liu H., Morrow J.D., Crews B.C., Marnett L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 1999, 59:4574-4577.
10. Dias W.B., Fajardo F.D., Graca-Souza A.V., Freire-de-Lima L., Vieira F., Girard M.F., Bouteille B., Previato J.O., Mendonca-Previato L., Todeschini A.R. Endothelial cell signalling induced by trans-sialidase from Trypanosoma cruzi. Cell. Microbiol. 2008, 10:88-99.
11. Duaso J., Rojo G., Cabrera G., Galanti N., Bosco C., Maya J.D., Morello A., Kemmerling U. Trypanosoma cruzi induces tissue disorganization and destruction of chorionic villi in an ex vivo infection model of human placenta. Placenta 2010, 31:705-711.
12. Faundez M., Lopez-Munoz R., Torres G., Morello A., Ferreira J., Kemmerling U., Orellana M., Maya J.D. Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox. Antimicrob. Agents Chemother. 2008, 52:1837-1839.
13. Garcia S., Ramos C.O., Senra J.F., Vilas-Boas F., Rodrigues M.M., Campos-de-Carvalho A.C., Ribeiro-Dos-Santos R., Soares M.B. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob. Agents Chemother. 2005, 49:1521-1528.
14. Gross M.D., Bielinski S.J., Suarez-Lopez J.R., Reiner A.P., Bailey K., Thyagarajan B., Carr J.J., Duprez D.A., Jacobs D.R. Circulating soluble intercellular adhesion molecule 1 and subclinical atherosclerosis: the coronary artery risk development in young adults study. Clin. Chem. 2012, 58:411-420.
15. Herrera R.N., Diaz E., Perez R., Chain S., Sant-Yacumo R., Rodriguez E., Bianchi J., Coviello A., Miotti J., Flores I., de la Serna F., Muntaner J., Berman S., Luciardi H. The prothrombotic state in early stages of chronic chagas' disease. Rev. Esp. Cardiol. 2003, 56:377-382.
16. Huang H., Calderon T.M., Berman J.W., Braunstein V.L., Weiss L.M., Wittner M., Tanowitz H.B. Infection of endothelial cells with Trypanosoma cruzi activates NF-kappaB and induces vascular adhesion molecule expression. Infect. Immun. 1999, 67:5434-5440.
17. Huang H., Yanagisawa M., Kisanuki Y.Y., Jelicks L.A., Chandra M., Factor S.M., Wittner M., Weiss L.M., Pestell R.G., Shtutin V., Shirani J., Tanowitz H.B. Role of cardiac myocyte-derived endothelin-1 in chagasic cardiomyopathy: molecular genetic evidence. Clin. Sci. (Lond.) 2002, 103(Suppl (48)):263SL 266S.
18. Huang W.C., Chan S.T., Yang T.L., Tzeng C.C., Chen C.C. Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel alpha-methylene-gamma-butyrolactone derivatives. Carcinogenesis 2004, 25:1925-1934.
19. Ishizuka T., Kawakami M., Hidaka T., Matsuki Y., Takamizawa M., Suzuki K., Kurita A., Nakamura H. Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin. Exp. Immunol. 1998, 112:464-470.
20. Keller T.T., Mairuhu A.T., de Kruif M.D., Klein S.K., Gerdes V.E., ten Cate H., Brandjes D.P., Levi M., van Gorp E.C. Infections and endothelial cells. Cardiovasc. Res. 2003, 60:40-48.
21. Kobayashi H., Boelte K.C., Lin P.C. Endothelial cell adhesion molecules and cancer progression. Curr. Med. Chem. 2007, 14:377-386.
22. Lannes-Vieira J., Silverio J.C., Pereira I.R., Vinagre N.F., Carvalho C.M., Paiva C.N., Silva da A.A. Chronic Trypanosoma cruzi-elicited cardiomyopathy: from the discovery to the proposal of rational therapeutic interventions targeting cell adhesion molecules and chemokine receptors - how to make a dream come true. Mem. Inst. Oswaldo Cruz 2009, 104(Suppl (1)):226-235.
23. Lannes-Vieira J., Silverio J.C., Pereira I.R., Vinagre N.F., Carvalho C.M.E., Paiva C.N., da Silva A.A. Chronic Trypanosoma cruzi-elicited cardiomyopathy: from the discovery to the proposal of rational therapeutic interventions targeting cell adhesion molecules and chemokine receptors - how to make a dream come true. Mem. Inst. Oswaldo Cruz 2009, 104:226-235.
24. Laucella S.A., Segura E.L., Riarte A., Sosa E.S. Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease. Clin. Exp. Immunol. 1999, 118:423-427.
25. Maggio A.B., Farpour-Lambert N.J., Montecucco F., Pelli G., Marchand L.M., Schwitzgebel V., Mach F., Aggoun Y., Beghetti M. Elevated E-selectin and diastolic blood pressure in diabetic children. Eur. J. Clin. Invest. 2012, 42:303-309.
26. Maier H.J., Schips T.G., Wietelmann A., Kruger M., Brunner C., Sauter M., Klingel K., Bottger T., Braun T., Wirth T. Cardiomyocyte-specific IkappaB kinase (IKK)/NF-kappaB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:11794-11799.
27. Manarin R., Pascutti M.F., Ruffino J.P., De Las Heras B., Bosca L., Bottasso O., Revelli S., Serra E. Benznidazole blocks NF-kappaB activation but not AP-1 through inhibition of IKK. Mol. Immunol. 2010, 47:2485-2491.
28. Marin-Neto J.A., Cunha-Neto E., Maciel B.C., Simoes M.V. Pathogenesis of chronic Chagas heart disease. Circulation 2007, 115:1109-1123.
29. Morris T., Stables M., Hobbs A., de Souza P., Colville-Nash P., Warner T., Newson J., Bellingan G., Gilroy D.W. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 2009, 183:2089-2096.
30. Munoz J., Gomez i Prat J., Gallego M., Gimeno F., Trevino B., Lopez-Chejade P., Ribera O., Molina L., Sanz S., Pinazo M.J., Riera C., Posada E.J., Sanz G., Portus M., Gascon J. Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). Acta Trop. 2009, 111:51-55.
31. National Research Council (U.S.), Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.) Guide for the Care and Use of Laboratory Animals 2011, National Academies Press, Washington, DC. 8th ed.
32. Petkova S.B., Huang H., Factor S.M., Pestell R.G., Bouzahzah B., Jelicks L.A., Weiss L.M., Douglas S.A., Wittner M., Tanowitz H.B. The role of endothelin in the pathogenesis of Chagas' disease. Int. J. Parasitol. 2001, 31:499-511.
33. Piaggio E., Sanceau J., Revelli S., Bottasso O., Wietzerbin J., Serra E. Trypanocidal drug benznidazole impairs lipopolysaccharide induction of macrophage nitric oxide synthase gene transcription through inhibition of NF-kappaB activation. J. Immunol. 2001, 167:3422-3426.
34. Pinazo M.J., Tassies D., Munoz J., Fisa R., Posada Ede J., Monteagudo J., Ayala E., Gallego M., Reverter J.C., Gascon J. Hypercoagulability biomarkers in Trypanosoma cruzi -infected patients. Thromb. Haemostasis 2011, 106:617-623.
35. Roldan V., Marin F., Lip G.Y., Blann A.D. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb. Haemostasis 2003, 90:1007-1020.
36. Ronco M.T., Manarin R., Frances D., Serra E., Revelli S., Carnovale C. Benznidazole treatment attenuates liver NF-kappaB activity and MAPK in a cecal ligation and puncture model of sepsis. Mol. Immunol. 2011, 48:867-873.
37. Rossi M.A., Bestetti R.B. The challenge of chagasic cardiomyopathy. The pathologic roles of autonomic abnormalities, autoimmune mechanisms and microvascular changes, and therapeutic implications. Cardiology 1995, 86:1-7.
38. Rossi M.A., Ramos S.G. Coronary microvascular abnormalities in Chagas' disease. Am. Heart J. 1996, 132:207-210.
39. Rossi M.A., Tanowitz H.B., Malvestio L.M., Celes M.R., Campos E.C., Blefari V., Prado C.M. Coronary microvascular disease in chronic Chagas cardiomyopathy including an overview on history, pathology, and other proposed pathogenic mechanisms. PLoS Negl. Trop. Dis. 2010, 4:e674.
40. Tanowitz H.B., Huang H., Jelicks L.A., Chandra M., Loredo M.L., Weiss L.M., Factor S.M., Shtutin V., Mukherjee S., Kitsis R.N., Christ G.J., Wittner M., Shirani J., Kisanuki Y.Y., Yanagisawa M. Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease. Infect. Immun. 2005, 73:2496-2503.
41. Tanowitz H.B., Machado F.S., Jelicks L.A., Shirani J., de Carvalho A.C., Spray D.C., Factor S.M., Kirchhoff L.V., Weiss L.M. Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Prog. Cardiovasc. Dis. 2009, 51:524-539.
42. Vilas Boas, L.G., Bestetti, R.B., Otaviano, A.P., Cardinalli-Neto, A., Nogueira, P.R. Outcome of Chagas cardiomyopathy in comparison to ischemic cardiomyopathy. Int. J. Cardiol., , in press. doi:10.1016/j.ijcard.2012.01.033.
43. Wang J., Dong S. ICAM-1 and IL-8 are expressed by DEHP and suppressed by curcumin through ERK and p38 MAPK in human umbilical vein endothelial cells. Inflammation 2012, 35:859-870.
44. Wijnstok N.J., Twisk J.W., Young I.S., Woodside J.V., McFarlane C., McEneny J., Hoekstra T., Murray L., Boreham C.A. Inflammation markers are associated with cardiovascular diseases risk in adolescents: the Young Hearts project 2000. J. Adolesc. Health 2010, 47:346-351.
45. Zakynthinos E., Pappa N. Inflammatory biomarkers in coronary artery disease. J. Cardiol. 2009, 53:317-333.